The Weston A. Price Foundation   Report issue

Foundation Phase 2
Founded: Washington D.C. United States (1999)

Organization Overview

First Clinical Trial
2018
NCT03260920
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

The Weston A. Price Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aphasia, Primary Progressive (Phase 2)

Dementia (Phase 2)

Frontotemporal Dementia (Phase 2)

Metabolic Syndrome (Phase 2)

Obesity (Phase 2)

Pick Disease of the Brain (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 5